ArticleBMC endocrine disorders2025
Association of serum adiponectin level with glycemic control and atherogenic lipid profile in Sudanese patients with type 2 diabetes mellitus.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating Adiponectin and Omentin Across Cardiometabolic Phenotypes: Links to Atherogenic Indices in Prediabetes and New-Onset Type 2 Diabetes.International journal of molecular sciences · 2026Article
- Insulin resistance and serum adiponectin levels in Nigerian patients with type 2 diabetes mellitus: a case-control study.BMC research notes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenesis of type 2 diabetes mellitus (type 2 DM) involves two major abnormalities: insulin resistance(IR) and impaired insulin secretion, both of which contribute to the inability to regulate blood glucose levels. Adiponectin, a hormone secreted by adipose tissue, plays a role in glucose metabolism and possesses insulin-sensitizing properties. Additionally, adiponectin may play a central role in protecting against atherosclerosis by reducing inflammation, lipid accumulation, and oxidative stress. It has also been reported to increase nitric oxide production in endothelial cells through the activation of nitric oxide synthase. The aim of this study was to investigate the association of serum adiponectin level with glycemic control and atherogenic lipid profile in Sudanese patients with type 2 DM.
methodsThis was a case-control study. Patients with type 2 DM (n = 202) and healthy controls (n = 100) were consented and enrolled. Systolic and diastolic blood pressures (mm Hg), weight (kg), and height (m) were measured, and body mass index (kg/m²) was calculated. Blood samples were collected after an overnight fast. Fasting blood glucose (FBG), haemoglobin A1c (HbA1c), and lipid profile were measured using enzymatic methods. Adiponectin levels were determined using a sandwich ELISA. Multiple regression analysis was conducted to assess the correlation of adiponectin levels with HbA1c and lipid profile parameters.
resultsAdiponectin levels were significantly lower in patients with type 2 DM compared to healthy controls (p < 0.001). Adiponectin was inversely correlated with HbA1c (β = −0.200, p = 0.005), total cholesterol (TC) (β = −0.140, p = 0.044), and low- density lipoprotein cholesterol (LDL-C) (β = −0.162, p = 0.022), and positively correlated with high-density lipoprotein cholesterol (HDL-C) (β = 0.160, p = 0.030). No correlation was observed with triglyceride (TG) levels. Patients with type 2 DM also exhibited significantly higher systolic and diastolic blood pressure, body mass index (BMI), fasting blood glucose (FBG), HbA1c, total cholesterol, and LDL-C levels, along with significantly lower HDL-C levels compared to healthy controls (p < 0.05).
conclusionsPatients with type 2 DM had decreased serum adiponectin levels. The present study supports that adiponectin levels are associated with glycemic control and an atherogenic lipid profile. Adiponectin can be considered clinically relevant both as a potential dual biomarker and as a therapeutic target for glycemic control and atherogenic dyslipidemia in patients with type 2 DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.